Amy Hall Email & Phone Number

West Chester, Pa, Us

Wilmington, Delaware, Us

Wilmington, Delaware, Us

Wilmington, Delaware, Us

Wilmington, Delaware, Us

Cambridge, Cambridgeshire, Gb

US team leader and strategic partner of a $6B peak year sales portfolio. Led ten direct and five indirect reports in the delivery of integrated customer insights, rigorous data analytics, forecasting and pipeline investment evaluations. • Launched 4 products in less than 3 years under accelerated approval timelines providing direct and indirect strategic launch support, including specialty distribution channel strategy • Led analysis for diagnostic investment business cases that secured >$2M of global team funding • Evaluated EMR, claims, lab, specialty pharmacy and specialty distribution data resources and optimized investments across the Oncology portfolio saving >$1M• Saved over $250k by influencing the decision to use internal vs. external resources to build an integrated marketing mix optimization and measurement framework to inform future Oncology portfolio investment decisions • Saved $200k by eliminating a data purchase and leveraging a preexisting data alternative. Incremental strategic benefit capitalized upon which provided sales teams visibility to opportunistic low efficacious dose prescribing• Identified a cross-portfolio messaging opportunity to ensure appropriate patient treatment decisions when tissue samples required HCP trade-off decisions between NSCLC EGFR and PD-L1 testing • Championed a strategic initiative to build a data platform that enabled operational efficiencies and enhanced the use of patient level data, including the identification of timely promotional interaction opportunities• Conceived, developed, and delivered a ‘Storytelling’ workshop that enabled skill development and an environment that fostered interaction of 100+ Insight & Analytics colleagues• Recruited, on-boarded, and built a diverse insight and data analytics team to support in-line, early launch and pipeline products in Gaithersburg, MD after the Oncology TA was reprioritized and moved from Wilmington, DE

Cambridge, Cambridgeshire, Gb

US team leader of nine growth portfolio insight and analytic direct reports that delivered actionable insights and strategic support to Cardiovascular, Respiratory, and Oncology brand teams (annual sales ~$5B) • Partnered with Brand Insight Directors to ensure the insight resources were allocated appropriately to support the portfolio needs, as well as ensure that workload was fairly balanced across team• Drove operational excellence and delivery of meaningful actionable insights through integration of portfolio and commercial insight teams, best practice sharing, implementation of new practices, and efficiencies across brands• Led Insight & Analytics functional responsibilities that included skill developmental workshops, talent management, preferred vendor reviews, and contract negotiations• Enabled effective Commercial Business and Executive Sales Director leadership meeting discussions

Cambridge, Cambridgeshire, Gb

US team leader that developed and executed Market Access and Payer strategy to ensure patient access and optimized pricing and contracting strategies for a $6B peak-year sales franchise, including leadership of 2 direct reports• Conducted extensive analysis of SEROQUEL XR and competitor performance at different access levels and recommended a change to the Medicaid Strategy as a result of Health Care Reform and CMS guidance implications • Collaborated with State Government Affairs, Ally, and Policy to transition the franchise from a long established and embedded open access position to broad access strategy as a result of advantaged access contract offers• Led development of the first AstraZeneca (AZ) promotionally approved price by indication resource that fundamentally changed the nature of payer value conversations • Led development of strategic messaging and promotional materials to deliver the brands’ value proposition to payers and improve awareness and perceptions of the brands’ formulary access and affordability with prescribers• Led brand forecast assumptions incorporating implications of an evolving payer landscape including payer mix, payer restrictions, contracting/rebate strategy, and Medicaid transitions (from state to Managed Care Organizations)• Optimized promotion and budget of sample and voucher programs, while enhancing the savings card benefit design which allowed broader patient utilization• Co-led a work stream focused on the Health Care Reform implications to the AZ portfolio in the Medicaid segment

Cambridge, Cambridgeshire, Gb

US team leader of the Oncology Franchise $1.6B annual sales (2008-2009) and ABRAXANE $400M annual sales (2006-2008) that provided strategic insights to ensure brand decisions were based on rigorous analyses and quality information • Enabled senior leaders to make appropriate business decisions by clarifying and quantifying the impact on the brand forecast growth opportunity of patients graduating from ARIMIDEX 5-year treatment • Led scenario planning and strategic evaluation of a key competitive clinical trial data, including collaboration with a global and US cross-functional team to develop strategic response and messaging• Led efforts to evaluate patient response to new product packaging and provided timely and objective feedback that enabled a leadership decision within 90 days of launch to discontinue and return to original packaging • Quantified a $160M 1st Line metastatic breast cancer opportunity that enabled the Leadership team to refocus resources appropriately to capture the opportunistic sales• Recognized for providing value beyond Brand Insight role through support of strategic development, training, communications, field engagement and promotional initiatives

Cambridge, Cambridgeshire, Gb

US team leader of a $1.3B Oncology annual sales portfolio, including leadership of 2 direct reports• Actively participated in the strategic decision making as a member of the Breast, Prostate and NSCLC Leadership • Analyzed and challenged the Oncology portfolio financial performance to guide leadership in decision making and timely reallocation of budget resources

Us

Managed, analyzed, consolidated and reported the financial activity of the $700 million annual plasma protein manufacturing production budget.

Led the start-up software company in external financial reporting, internal management budgeting and reporting, cash optimization and internal control.

Managed, analyzed, consolidated and reported the financial results for the North America and US Commercial Operations division.

Conducted audits, developed financial statements, and prepared tax returns for various industry clients including physician practices, manufacturing, construction and long-term contractors, wholesale distributors, television broadcasting, retailing, not-for-profit organizations and governmental units.